Selected article for: "antiviral drug and effective approach"

Author: Yu, Jin
Title: Organoids: A New Model for SARS-CoV-2 Translational Research
  • Cord-id: x9c41mdv
  • Document date: 2021_2_28
  • ID: x9c41mdv
    Snippet: The 2019-novel coronavirus (SARS-CoV-2) pneumonia epidemic is a thorny public health problem faced by health officials and a major cause of concern for health professionals. However, the currently used immortalized cell lines and animal models, though easy to manipulate, can not thoroughly simulate real viral activity due to a lack of target cells, species isolation, and insufficient adequate tissues and organs for clinical research. Organoid that emerges as an effective model and time-saving ap
    Document: The 2019-novel coronavirus (SARS-CoV-2) pneumonia epidemic is a thorny public health problem faced by health officials and a major cause of concern for health professionals. However, the currently used immortalized cell lines and animal models, though easy to manipulate, can not thoroughly simulate real viral activity due to a lack of target cells, species isolation, and insufficient adequate tissues and organs for clinical research. Organoid that emerges as an effective model and time-saving approach can simulate the viral life cycle in vitro and explore a therapeutic target for antiviral drug development. The 3D tissue cultures contain patient-specific stem cells in vitro to mimic the complexity of real tissue within the 3D microstructure that has the same functionality as the tissue of interest. It avoids the problems such as the distortion of genetic markers and animal ethics of using 2D cultures for animal testing and can be employed in studies of specific-organ viral infections to fully understand the physiopathological mechanism of SARS-CoV-2 infection for vaccine research and development.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute kidney injury: 1, 2, 3, 4, 5, 6, 7
    • absence presence and acute myocardial infarction: 1, 2
    • absence presence and acute respiratory failure: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • absence presence and liver damage: 1, 2
    • absence presence and liver function: 1, 2
    • absence presence and liver infection: 1
    • activation initiate and acute injury: 1
    • activation initiate and acute myocardial infarction: 1
    • acute injury and adequate animal model: 1
    • acute injury and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute injury and liver duct: 1, 2
    • acute injury and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute injury and liver infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and liver damage: 1, 2, 3, 4, 5, 6
    • acute kidney injury and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute kidney injury and liver infection: 1, 2, 3, 4, 5, 6, 7, 8
    • acute myocardial infarction and liver damage: 1
    • acute myocardial infarction and liver function: 1
    • acute respiratory failure and liver damage: 1, 2, 3, 4, 5